Roghayyeh Baghban, Mohammad Reza Khalili, Athar Zareei, Mohammad Reza Talebnejad
{"title":"用纳米技术推进青光眼治疗:眼科的新前沿。","authors":"Roghayyeh Baghban, Mohammad Reza Khalili, Athar Zareei, Mohammad Reza Talebnejad","doi":"10.1016/j.ijpharm.2025.126210","DOIUrl":null,"url":null,"abstract":"<p><p>Glaucoma is defined by the progressive degeneration of retinal ganglion cells (RGCs), which ultimately results in permanent vision loss. Reducing Intraocular pressure (IOP) is now the primary therapeutic approach; however, it merely delays the disease's progression and does not provide recovery. However, the present approaches, like eye drops, have low adherence and short-term efficacy, and procedures are susceptible to failure because of wound fibrosis. By encapsulating antifibrotic and IOP-lowering medications in biodegradable nanoparticles (NPs), nanotechnology provides a method that ensures continuous release to protect injured eye cells. Additionally, nanotechnology makes it possible for patients to get therapy in a variety of convenient ways, such as contact lenses, ocular inserts, and eye drops. This review highlights the potential therapeutic applications of nanotechnology for managing glaucoma.</p>","PeriodicalId":14187,"journal":{"name":"International Journal of Pharmaceutics","volume":" ","pages":"126210"},"PeriodicalIF":5.2000,"publicationDate":"2025-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Advancing glaucoma treatment with nanotechnology: a new frontier in ophthalmology.\",\"authors\":\"Roghayyeh Baghban, Mohammad Reza Khalili, Athar Zareei, Mohammad Reza Talebnejad\",\"doi\":\"10.1016/j.ijpharm.2025.126210\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Glaucoma is defined by the progressive degeneration of retinal ganglion cells (RGCs), which ultimately results in permanent vision loss. Reducing Intraocular pressure (IOP) is now the primary therapeutic approach; however, it merely delays the disease's progression and does not provide recovery. However, the present approaches, like eye drops, have low adherence and short-term efficacy, and procedures are susceptible to failure because of wound fibrosis. By encapsulating antifibrotic and IOP-lowering medications in biodegradable nanoparticles (NPs), nanotechnology provides a method that ensures continuous release to protect injured eye cells. Additionally, nanotechnology makes it possible for patients to get therapy in a variety of convenient ways, such as contact lenses, ocular inserts, and eye drops. This review highlights the potential therapeutic applications of nanotechnology for managing glaucoma.</p>\",\"PeriodicalId\":14187,\"journal\":{\"name\":\"International Journal of Pharmaceutics\",\"volume\":\" \",\"pages\":\"126210\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"International Journal of Pharmaceutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.ijpharm.2025.126210\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Pharmaceutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.ijpharm.2025.126210","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Advancing glaucoma treatment with nanotechnology: a new frontier in ophthalmology.
Glaucoma is defined by the progressive degeneration of retinal ganglion cells (RGCs), which ultimately results in permanent vision loss. Reducing Intraocular pressure (IOP) is now the primary therapeutic approach; however, it merely delays the disease's progression and does not provide recovery. However, the present approaches, like eye drops, have low adherence and short-term efficacy, and procedures are susceptible to failure because of wound fibrosis. By encapsulating antifibrotic and IOP-lowering medications in biodegradable nanoparticles (NPs), nanotechnology provides a method that ensures continuous release to protect injured eye cells. Additionally, nanotechnology makes it possible for patients to get therapy in a variety of convenient ways, such as contact lenses, ocular inserts, and eye drops. This review highlights the potential therapeutic applications of nanotechnology for managing glaucoma.
期刊介绍:
The International Journal of Pharmaceutics is the third most cited journal in the "Pharmacy & Pharmacology" category out of 366 journals, being the true home for pharmaceutical scientists concerned with the physical, chemical and biological properties of devices and delivery systems for drugs, vaccines and biologicals, including their design, manufacture and evaluation. This includes evaluation of the properties of drugs, excipients such as surfactants and polymers and novel materials. The journal has special sections on pharmaceutical nanotechnology and personalized medicines, and publishes research papers, reviews, commentaries and letters to the editor as well as special issues.